Entities / Company
VIR Biotechnology.
biotech company
- Reports this week
- 0
- Active events
- 0
- Connections
- 40
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Janet Napolitano and Renaissance Technologies filed reports regarding buying and selling shares of Vir Biotechnology stock with the SEC.Some support1 report
-
Brii Biosciences and VIR Biotechnology engaged regarding chronic hepatitis B virus therapies, including an arbitration over manufacturing technology transfer.Some support3 reports
Gone quiet
No new reports in 90+ days-
The ECLIPSE program is the registrational program for Vir Biotechnology.Some support1 report
-
The ECLIPSE program is the registrational program for Vir Biotechnology, and the trial supports global marketing in Europe.Some support1 report
-
Dr. Alan J. Korman was appointed to Invenra's Scientific Advisory Board, where Roland Green serves as CEO.Some support1 report
-
Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.Some support1 report1 development inside
-
VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.Some support1 report
-
Vir Biotechnology shares lost 30.4% on August 7, 2025, against a gain in the S&P 500.Some support1 report
-
CEO of VIR Biotechnology participated in a conference chat hosted by Morgan Stanley on August 26, 2025.Some support1 report
-
Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around VIR Biotechnology this week
News at the entities that move VIR Biotechnology most-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves VIR Biotechnology
-
Renaissance Technologies TransactionalRenaissance Technologies holds a significant stake in Lite Strategy, Inc., whose stock trades on the Nasdaq exchange.Moves VIR Biotechnology
-
Netherlands Shared contextAruba, Curaçao, Sint Maarten, and the Netherlands collaborated on digitizing historical meteorological archives.Moves VIR Biotechnology
Connections
The 4 strongest of 40, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SEC Structural
VIR Biotechnology is subject to mandatory filings and oversight by the U.S. Securities and Exchange Commission.
-
Janet Napolitano Transactional
Janet Napolitano sold shares of VIR Biotechnology.
-
Renaissance Technologies Transactional
Renaissance Technologies increased its investment holdings in VIR Biotechnology shares.
-
Netherlands Shared context
VIR Biotechnology conducts clinical data presentations within the Netherlands.
History
Events by the month they beganAugust 2026
1 eventJune 2026
8 events- The ECLIPSE program is the registrational program for Vir Biotechnology.
- The ECLIPSE program is the registrational program for Vir Biotechnology, and the trial supports global marketing in Europe.
- Dr. Alan J. Korman was appointed to Invenra's Scientific Advisory Board, where Roland Green serves as CEO.
- Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
- VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.
- Vir Biotechnology shares lost 30.4% on August 7, 2025, against a gain in the S&P 500.
- CEO of VIR Biotechnology participated in a conference chat hosted by Morgan Stanley on August 26, 2025.
- Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.